Akebia Therapeutics

165 articles with Akebia Therapeutics

• Akebia Announces First Quarter 2017 Financial Results

  5/10/2017

• Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

  5/5/2017

• Why Akebia, Even With Otsuka Pharma's Big Deal, May Need To Be Acquired

  4/27/2017

• Otsuka Pharma Believes in Akebia, Commits Another $865 Million to Expand Anemia Deal

  4/26/2017

• Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

  4/7/2017

• Akebia Announces Publication Of Phase IIa Results For Vadadustat In Patients With Anemia Related To Chronic Kidney Disease

  3/28/2017

• Akebia Spinoff Aerpio Scores $40 Million

  3/16/2017

• Akebia Announces Fourth Quarter And Full-Year 2016 Financial Results

  3/7/2017

• Akebia To Host Conference Call On March 6th To Discuss Full-Year 2016 Financial Results And Corporate Highlights

  3/1/2017

• Akebia Licenses Portfolio Of Novel HIF Compounds From Johnson & Johnson Innovation

  2/13/2017

• Akebia Forges $1B U.S. Deal with Otsuka Pharma on Late-Stage Drug

  12/20/2016

• Akebia Prevails in Additional European Patent Dispute

  12/12/2016

• Akebia Announces Third Quarter 2016 Financial Results

  11/10/2016

• Akebia Announces Publication Highlighting Potential Benefits Of HIF Treatments For Patients With Renal Anemia

  9/26/2016

• Akebia Announces Publication Of Phase IIb Data For Vadadustat In Non-Dialysis Patients With Anemia Related To Chronic Kidney Disease

  9/19/2016

• Akebia To Present At Upcoming Investor Conferences

  9/7/2016

• Akebia Announces Publication Highlighting Need For New Solutions In Treating Dialysis Patients

  8/22/2016

• Akebia Initiates INNO2VATE Phase 3 Program For Vadadustat In Dialysis Patients With Anemia Related To Chronic Kidney Disease

  8/9/2016

• Akebia Announces Second Quarter 2016 Financial Results

  8/9/2016

• Akebia Appoints Scott A. Canute To Its Board Of Directors

  8/3/2016